Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

Validation of a Novel Type II HER2 Inhibitor Through Preclinical Studies Across Various Cancer Models (AACR Poster)

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

NeuralPLexer: Multiscale generative diffusion with equivariant transformers

A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers

#COVIDisAirborne: AI-enabled multiscale computational microscopy of delta SARS-CoV-2 in a respiratory aerosol

UNiTE: Unitary N-body tensor equivariant network with applications to quantum chemistry

OrbNet Denali: A machine learning potential for biological and organic chemistry with semi-empirical cost and DFT accuracy

Multi-Task Learning for Electronic Structure to Predict and Explore Molecular Potential Energy Surfaces

OrbNet: Deep learning for quantum chemistry using symmetry-adapted atomic-orbital features

AI-driven discovery of 1000-fold selective and CNS-penetrant Her2 inhibitor

The Bio Report: A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

Ascenta Investor Day: A Conversation with David M. Rubenstein and Tom Miller

Tom Miller Presents at the NVIDIA Spring GTC23 Event

Freeflow Founders Session

Caltech Heritage Project: A profile on Tom Miller, CEO of Iambic

#COVIDisAirborne: Tom Miller presents Gordon Bell publication at SC21

Tom Miller Presents at PBSS Symposium 2021

Tom Miller Presents at the NVIDIA Fall GTC21 Event

Tom Miller Participates in NVIDIA Grand Challenge Panel During Spring GTC21

Tom Miller Presents at the NVIDIA Spring GTC21 Event